Zweig-DiMenna Associates’s Biogen BIIB Stock Holding History

Zweig-DiMenna Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-900	Closed	-$246K	–	210
2017 Q1	$246K	Hold	900	–	–	0.02%	147
2016 Q4	$255K	Buy	+900	New	+$267K	0.02%	169
2016 Q1	–	Sell	-30,000	Closed	-$9.19M	–	191
2015 Q4	$9.19M	Buy	+30,000	New	+$8.62M	0.46%	78
2015 Q3	–	Sell	-11,185	Closed	-$4.52M	–	230
2015 Q2	$4.52M	Sell	11,185 -61,012	-85%	-$24.5M	0.25%	91
2015 Q1	$30.5M	Buy	72,197 +67,297	+1,373%	+$26.5M	1.28%	18
2014 Q4	$1.66M	Sell	4,900 -33,937	-87%	-$11M	0.07%	132
2014 Q3	$12.8M	Buy	38,837 +38,037	+4,755%	+$12.5M	0.56%	63
2014 Q2	$252K	Sell	800 -25,975	-97%	-$7.82M	0.01%	209
2014 Q1	$8.19M	Buy	26,775 +25,875	+2,875%	+$8.21M	0.48%	73
2013 Q4	$252K	Buy	+900	New	+$233K	0.01%	193

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Zweig-DiMenna Associates's BIIB Position: Q2 2017 in Review

Zweig-DiMenna Associates sold out of Biogen (BIIB) in Q2 2017, closing a stake of 900 shares — an estimated $246K sold.

Zweig-DiMenna Associates first reported a position in BIIB in Q4 2013 and held it in 10 quarters. The position peaked at $30.5M in Q1 2015. 993 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

Zweig-DiMenna Associates reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
Zweig-DiMenna Associates sold 900 Biogen shares in Q2 2017, an estimated $246K.
Zweig-DiMenna Associates first reported a position in Biogen in Q4 2013 and held it in 10 quarters.
Zweig-DiMenna Associates's Biogen position peaked at $30.5M in Q1 2015.
993 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2017, filed 7 Aug 2017.